⌕
Transmedics Group · TMDX · Nasdaq
Tenet 53 · Mixed
Compare
$92.21+0.91%At closeTenet 53 · Mixed
$92.21+0.83 (+0.91%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Transmedics Group (TMDX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~111.5%/yr (FY21→FY25), net margin 31.4%; free cash flow runs at 70% of net income. Check the accrual gap. Worth your attention in FY25: Share count (+46.8%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲37.1%
605.5
FY21→FY25CAGR +111.5%/yr
Net income ($M)▲436.6%
190.3
one-off year: see footnoteCAGR —
Free cash flow ($M)—
133.6
FY21→FY25CAGR —
Diluted EPS▲382.2%
4.87
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+46.8%

27.6mn → 40.5mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$59.3M

−54.3% YoY in FY25 · 9.8% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)605.5Revenue−242.7COGS362.8Gross profit−69.1R&D−185.2SG&A108.6Op income81.7Tax & other190.3Net income

31¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
705335180%sector median net margin ~4%FY21FY25

Over this window: gross 69.9% → 59.9%. Net margin 31.4% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
727,650.0605,494.0441,540.0241,623.093,459.030,262.0▲37.1%+111.5%
Cost of revenue
301,220.0242,688.0179,459.087,530.028,187.09,103.0▲35.2%+127.2%
Gross profit
426,430.0362,806.0262,081.0154,093.065,272.021,159.0▲38.4%+103.5%
Research & development
106,394.069,055.055,968.063,267.026,812.022,304.0▲23.4%+32.6%
Selling, general & admin
233,589.0185,168.0168,617.0119,553.069,897.038,283.0▲9.8%+48.3%
Total operating expenses
339,983.0254,223.0224,585.0182,820.096,709.060,587.0▲13.2%+43.1%
Operating incomefeeds ROC rank
86,447.0108,583.037,496.0−28,727.0−31,437.0−39,428.0▲189.6%—
Other income, net
−12,823.0−1,061.0−1,716.02,056.0−4,728.0−4,751.0——
Pretax income
73,624.0107,522.035,780.0−26,671.0−36,165.0−44,179.0▲200.5%—
Income tax
−70,829.0−82,769.0316.0−1,643.066.036.0——
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
144,453.0190,291.035,464.0−25,028.0−36,231.0−44,215.0▲436.6%—
Per share
Diluted EPSbuyback-sensitive
3.664.871.01−0.77−1.23−1.60▲382.2%—
Diluted shares (mn)
40.8340.5435.2232.5229.5627.62▲15.1%+10.1%
Margins
Gross margin39th pct in Healthcare
58.6%59.9%59.4%63.8%69.8%69.9%▲0.6pp−10.0pp
Operating margin
11.9%17.9%8.5%−11.9%−33.6%−130.3%▲9.4pp+148.2pp
Net margin85th pct in Healthcare
19.9%31.4%8.0%−10.4%−38.8%−146.1%▲23.4pp+177.5pp
† TTM = trailing four quarters through 2026-09-30.FY25 effective tax rate was −77% vs a −0% norm for this window, likely a one-time item; see the filing.
FY19 – FY20 · 2 more years
Unlock the full history →
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-24 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Transmedics Group's revenue last fiscal year?

Transmedics Group reported revenue of $605.5M in fiscal 2025, up 37.1% from fiscal 2024.

What was Transmedics Group's net income?

Transmedics Group reported net income of $190.3M in fiscal 2025, a net margin of 31.4%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.